News
-
![]()
Press Releases
-
![Informative content aimed at educating the public about lung cancer, early detection methods, the importance of biomarkers, and general health tips related to cancer prevention and care.]()
Educational Articles
-
![Detailed scientific studies and findings related to lung cancer detection, biomarker research, and other relevant medical research conducted or published by Cizzle Bio or related entities.]()
Research Papers
Cizzle Bio News
Stay informed with the latest updates on Cizzle Bio's milestones, industry news, and significant events. Here, you will find:
-
![Business professionals reviewing company milestones and progress reports in lung cancer diagnostics, highlighting key achievements in medical innovation.]()
Company Milestones
Discover our key achievements and progress in developing cutting-edge lung cancer diagnostics.
-
![Digital collage of news screens showcasing the latest trends and advancements in the biotechnology field, highlighting industry news and updates.]()
Industry News
Keep up with the latest trends and advancements in the biotechnology field.
-
![Doctor and business professional shaking hands, symbolizing strategic partnerships and collaborations to enhance cancer detection efforts.]()
Collaborations and Partnerships
Learn about our strategic partnerships and collaborative efforts to enhance cancer detection.
-
![Doctor presenting at a conference, discussing significant events and advancements in healthcare and biotechnology, highlighting Cizzle Bio's impact.]()
Significant Events
Get insights into important events and conferences that highlight our impact on healthcare and biotechnology.
Latest
Dr. Warren Kibbe Joins NCI as Deputy Director for Data Science, Ushering in New Era of AI-Driven Cancer Research
NCI’s new Deputy Director for Data Science, Dr. Warren Kibbe, aims to revolutionize cancer research using AI and big data. Learn about his goals and their impact on cancer detection and treatment advancements.
Cizzle Biotechnology Expanding into the USA and Transforming Cancer Screening
In a recent interview, Dr. Allan Syms shares how Cizzle Bio, Inc. is leading the charge in early lung cancer detection in the U.S. with its innovative CIZ1B biomarker test. Find out more about their expansion and clinical collaborations.
Cizzle Biotechnology Secures $300,000 Initial Royalty in North American Lung Cancer Test Agreement
Cizzle Biotechnology secures a $300,000 upfront royalty in its strategic licensing agreement with Cizzle Bio, Inc., advancing the rollout of its early lung cancer detection test across North America.
Cizzle Bio, Inc. Partners with Moffitt Cancer Center to Advance Lung Cancer Detection
Cizzle Bio, Inc. is proud to collaborate with Moffitt Cancer Center to clinically evaluate the CIZ1B biomarker test for early-stage lung cancer detection. This partnership represents a significant step in advancing lung cancer diagnostics and improving patient care.
Advancing Lung Cancer Detection: Cizzle Biotechnology's Innovative Blood Test
Explore Cizzle Biotechnology's new blood test for early lung cancer detection, featuring the CIZ1B biomarker. Watch the video to learn about the development process and its potential impact.
Cizzle Bio's Major Milestone: CIZ1B Biomarker Test Selected for US Cancer Study
Cizzle Bio, Inc.'s CIZ1B biomarker test has been selected for a significant US cancer study, marking a major milestone in lung cancer detection. Read more about this exciting development.
Revolutionizing Lung Cancer Detection: Cizzle Bio, Inc.'s New Partnership
Cizzle Bio, Inc. announces a groundbreaking partnership with Cizzle Biotechnology Holdings PLC, ushering in a new era of lung cancer detection technology in North America. Learn about how the advanced CIZ1B biomarker is set to change the landscape of healthcare.
Cizzle Biotechnology Holdings plc Annual Report and Financial Statements 2023 Summary
Read the 2023 annual report summary for Cizzle Biotechnology Holdings plc, highlighting strategic licensing, financial performance, research developments, and future plans for early lung cancer detection.
Cizzle Biotechnology's £0.62 Million Fundraising and Strategic Developments
Cizzle Biotechnology raises £0.62 million to advance the CIZ1B biomarker test for early lung cancer detection and appoints Allenby Capital as joint broker. Discover the strategic milestones and future plans.
ProteoGenix and Cizzle Biotechnology Collaboration Advances Early Lung Cancer Detection
ProteoGenix and Cizzle Biotechnology have developed new antibodies for early lung cancer detection. Explore the advancements and future impacts of this innovative partnership.
Strategic Licensing and Partnership: Cizzle Bio Inc.
Discover how Cizzle Biotechnology's new partnership aims to revolutionize lung cancer detection in North America through the CIZ1B biomarker test. Learn more about the strategic licensing agreement and its benefits.
Major Step Forward in Cizzle Biotechnology's Programme with Bio-Techne
Cizzle Biotechnology Holdings PLC announces a major advancement in its partnership with Bio-Techne, focusing on the CIZ1B biomarker test for early lung cancer detection. Discover the key developments and future outlook.
NCI’s new Deputy Director for Data Science, Dr. Warren Kibbe, aims to revolutionize cancer research using AI and big data. Learn about his goals and their impact on cancer detection and treatment advancements.